Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620339 | 0.92 | NPC1 (0.44) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL26620044 | 0.90 | CYP2D6 (0.46) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL24315782 | 0.90 | CYP2D6 (0.46) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL24316060 | 0.88 | PTGDR2 (0.48) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL26620499 | 0.86 | NPC1 (0.45) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL26620168 | 0.86 | PTGDR2 (0.47) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL27010308 | 0.85 | NPC1 (0.44) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL26620496 | 0.85 | PTGDR2 (0.46) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL24317323 | 0.84 | NPC1 (0.43) | NPC1PTGDR2USP2CYP3A4CYP2C9 | |
| SCHEMBL27010306 | 0.84 | PTGDR2 (0.46) | NPC1PTGDR2USP2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | NPC1 1565/4885PTGDR2 3825/4885USP2 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.